Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ionis Pharmaceuticals Inc (IONS)  
$40.16 0.77 (1.88%) as of 4:30 Wed 5/8


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 143,470,000
Market Cap: 5.76(B)
Last Volume: 998,037 Avg Vol: 995,265
52 Week Range: $35.18 - $53.55
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  292
Guru Rank Value     : 4.1
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ionis Pharmaceuticals is engaged in RNA-targeted therapeuty. Co.'s commercial products are SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA injection for intrathecal use is a survival motor neuron-2 directed antisense medicine indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI injection is an RNA-targeted medicine indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 11,298 469,764 507,366 634,895
Total Sell Value $477,835 $23,553,002 $25,162,121 $30,224,270
Total People Sold 4 12 13 13
Total Sell Transactions 4 44 52 78
End Date 2024-02-09 2023-11-08 2023-05-10 2022-05-10

   
Records found: 1983
  Page 3 of 80  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Swayze Eric EVP Research   •       –      –    2024-01-16 4 OE $0.00 $0 I/I 21 94     -
   Swayze Eric EVP Research   •       –      –    2024-01-16 4 OE $0.00 $0 D/D 17,069 49,585     -
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2024-01-16 4 OE $0.00 $0 D/D 15,162 53,332     -
   Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc   •       –      –    2024-01-16 4 OE $0.00 $0 D/D 15,062 39,374     -
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2024-01-16 4 OE $0.00 $0 D/D 22,487 99,573     -
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2024-01-12 4 S $53.50 $427,999 D/D (8,000) 38,170 24%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2024-01-12 4 OE $32.60 $260,800 D/D 8,000 46,170     -
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2023-12-28 4 D $50.50 $556,965 D/D (11,029) 36,999     -
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2023-12-28 4 OE $47.34 $544,410 D/D 11,500 48,028     -
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2023-12-28 4 D $50.50 $2,211,799 D/D (43,798) 77,086     -
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2023-12-28 4 OE $47.34 $2,140,952 D/D 45,225 120,884     -
   Swayze Eric EVP Research   •       –      –    2023-12-28 4 S $50.19 $1,360,081 D/D (27,100) 32,516 19%     
   Swayze Eric EVP Research   •       –      –    2023-12-28 4 OE $47.34 $1,282,914 D/D 27,100 59,616     -
   Parshall B Lynne Director   –       •      –    2023-12-28 4 S $50.19 $2,134,223 D/D (42,525) 82,588 19%     
   Parshall B Lynne Director   –       •      –    2023-12-28 4 OE $47.34 $2,013,134 D/D 42,525 125,113     -
   Parshall B Lynne Director   –       •      –    2023-12-27 4 S $50.23 $2,511,515 D/D (50,000) 82,588 18%     
   Parshall B Lynne Director   –       •      –    2023-12-27 4 OE $47.34 $2,367,000 D/D 50,000 132,588     -
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2023-12-26 4 S $51.46 $1,286,575 D/D (25,000) 36,052 20%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2023-12-26 4 OE $47.34 $1,183,500 D/D 25,000 61,052     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2023-12-26 4 S $51.46 $1,071,717 D/D (20,825) 40,355 20%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2023-12-26 4 OE $47.34 $985,856 D/D 20,825 61,180     -
   Parshall B Lynne Director   –       •      –    2023-12-26 4 S $51.46 $1,292,390 D/D (25,113) 82,588 20%     
   Parshall B Lynne Director   –       •      –    2023-12-26 4 OE $47.34 $1,188,849 D/D 25,113 107,701     -
   Geary Richard S EVP, Chief Development Officer   •       –      –    2023-12-21 4 S $49.29 $202,681 D/D (4,112) 72,961 15%     
   Geary Richard S EVP, Chief Development Officer   •       –      –    2023-12-21 4 OE $47.34 $194,662 D/D 4,112 77,073     -
  1983 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 80
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us